Patients with macular edema secondary to noninfectious uveitis who were treated with suprachoroidally injected triamcinolone acetonide gained significantly more vision when compared with a sham-treated cohort.
“This phase 3 randomized controlled trial demonstrated that suprachoroidally administered corticosteroid was effective in the reduction of macular edema in patients with noninfectious uveitis with nearly 50% of patients experiencing significant visual acuity gain. In addition, the safety results were favorable with a low rate of cataract and intraocular pressure response. These
Uncategorized